Primary Vitreoretinal Lymphoma (PVRL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Primary vitreoretinal lymphoma (PVRL) is a rare B-cell intraocular malignancy, commonly considered a subset of primary central nervous system (CNS) lymphoma. Brain dissemination occurs in 60–90% of patients, and it is the cause of the high mortality and morbidity of the disease. PVRL involves the vitreous, the retina, and the retinal pigment epithelium (RPE). According to the literature, around 15–20% of patients with primary central nervous system lymphoma (PCNSL) will develop PVRL later. The majority of PVRL is of B-cell origin. However, T-cell lymphomas and T-cell-rich lymphomas can also develop within the eye.
- PVRL has an approximate incidence in ~20% of patients with PCNSL and 0.03 to 0.1 cases per 100,000 people per year in the US. PVRL usually affects adults in the fifth-sixth decades of life.
Thelansis’s “Primary Vitreoretinal Lymphoma (PVRL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Vitreoretinal Lymphoma (PVRL) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Primary Vitreoretinal Lymphoma (PVRL) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Primary Vitreoretinal Lymphoma (PVRL) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment